Y-mAbs Therapeutics, Inc. (YMAB): Price and Financial Metrics


Y-mAbs Therapeutics, Inc. (YMAB): $4.24

-0.26 (-5.78%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

YMAB POWR Grades

  • Growth is the dimension where YMAB ranks best; there it ranks ahead of 89.21% of US stocks.
  • YMAB's strongest trending metric is Stability; it's been moving up over the last 179 days.
  • YMAB's current lowest rank is in the Momentum metric (where it is better than 4.51% of US stocks).

YMAB Stock Summary

  • The ratio of debt to operating expenses for Y-MABS THERAPEUTICS INC is higher than it is for about only 5.69% of US stocks.
  • Over the past twelve months, YMAB has reported earnings growth of 242.74%, putting it ahead of 93.16% of US stocks in our set.
  • In terms of volatility of its share price, YMAB is more volatile than 85.59% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Y-MABS THERAPEUTICS INC, a group of peers worth examining would be DCPH, TERN, UBX, API, and GWH.
  • Visit YMAB's SEC page to see the company's official filings. To visit the company's web site, go to www.ymabs.com.

YMAB Valuation Summary

  • YMAB's price/sales ratio is 4.2; this is 12.5% lower than that of the median Healthcare stock.
  • Over the past 51 months, YMAB's price/earnings ratio has gone up 24.

Below are key valuation metrics over time for YMAB.

Stock Date P/S P/B P/E EV/EBIT
YMAB 2022-11-25 4.2 1.7 -1.4 -0.5
YMAB 2022-11-23 4.3 1.7 -1.4 -0.6
YMAB 2022-11-22 4.2 1.7 -1.4 -0.5
YMAB 2022-11-21 4.0 1.6 -1.3 -0.5
YMAB 2022-11-18 4.1 1.7 -1.3 -0.5
YMAB 2022-11-17 4.0 1.6 -1.3 -0.5

YMAB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • YMAB has a Quality Grade of C, ranking ahead of 28.99% of graded US stocks.
  • YMAB's asset turnover comes in at 0.183 -- ranking 204th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows YMAB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.183 0.992 -10.948
2021-03-31 0.146 0.996 -77.742
2020-12-31 0.130 1.000 45.423
2020-09-30 0.000 NA 33.823
2020-06-30 0.000 NA 26.410
2020-03-31 0.000 NA 20.272

YMAB Price Target

For more insight on analysts targets of YMAB, see our YMAB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $55.00 Average Broker Recommendation 1.36 (Strong Buy)

YMAB Stock Price Chart Interactive Chart >

Price chart for YMAB

YMAB Price/Volume Stats

Current price $4.24 52-week high $20.48
Prev. close $4.50 52-week low $2.94
Day low $4.06 Volume 630,000
Day high $4.54 Avg. volume 563,043
50-day MA $9.09 Dividend yield N/A
200-day MA $12.24 Market Cap 185.15M

Y-mAbs Therapeutics, Inc. (YMAB) Company Bio


Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is based in New York, New York.


YMAB Latest News Stream


Event/Time News Detail
Loading, please wait...

YMAB Latest Social Stream


Loading social stream, please wait...

View Full YMAB Social Stream

Latest YMAB News From Around the Web

Below are the latest news stories about Y-MABS THERAPEUTICS INC that investors may wish to consider to help them evaluate YMAB as an investment opportunity.

Analysts Offer Insights on Healthcare Companies: Microbot Medical (MBOT), Y-Mabs Therapeutics (YMAB) and Acer Therapeutics (ACER)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Microbot Medical (MBOT – Research Report), Y-Mabs Therapeutics (YMAB – Research Report) and Acer Therapeutics (ACER – Research Report) with bullish sentiments. Microbot Medical (MBOT) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Microbot Medical, with a price target of $20.00. The company's shares closed last Friday at $4.06, close to its 52-week low of $3.36. According to TipRanks.

Christine Brown on TipRanks | November 21, 2022

BMO Capital Keeps Their Buy Rating on Y-Mabs Therapeutics (YMAB)

BMO Capital analyst Etzer Darout maintained a Buy rating on Y-Mabs Therapeutics (YMAB - Research Report) today and set a price target of $12.00. The company's shares opened today at $3.75.According to TipRanks, Darout is a 5-star analyst with an average return of 21.1% and a 39.24% success rate. Darout covers the Healthcare sector, focusing on stocks such as Y-Mabs Therapeutics, ImmunoGen, and Seagen.In addition to BMO Capital, Y-Mabs Therapeutics also received a Buy from H.C. Wainwright's Robert Burns in a report issued on October 31. However, on the same day, Morgan Stanley maintained a Hold rating on Y-Mabs Therapeutics (NASDAQ: YMAB).

Jason Carr on TipRanks | November 9, 2022

YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Tops Revenue Estimates

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 16% and 7.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 7, 2022

Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Q3 2022 DANYELZA® record product revenues of $12.5 million, YoY growth of 40% and 28% sequential increase compared to Q2 2022DANYELZA marketing authorization granted in Israel; regulatory filing submitted in BrazilManagement reiterates financial guidance, including anticipated 2022 full-year DANYELZA® revenue of $45-$50 millionCash position of $114.5 million as of September 30, 2022, anticipated runway into mid-2024 The Company will host a conference call on Tuesday, November 8, 2022, at 4 p.m.

Yahoo | November 7, 2022

Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022

NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter that ended September 30, 2022, on Monday, November 7, 2022, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, November 8, 2022, at 4:00 p.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, foun

Yahoo | November 2, 2022

Read More 'YMAB' Stories Here

YMAB Price Returns

1-mo 41.33%
3-mo -73.35%
6-mo -67.06%
1-year -74.07%
3-year -87.45%
5-year N/A
YTD -73.84%
2021 -67.26%
2020 58.43%
2019 53.64%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7278 seconds.